These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

628 related items for PubMed ID: 30139780

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
    Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators.
    Lancet; 2016 Oct 29; 388(10056):2115-2127. PubMed ID: 27609408
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
    Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X.
    Curr Med Res Opin; 2017 Sep 29; 33(9):1605-1613. PubMed ID: 28644104
    [Abstract] [Full Text] [Related]

  • 7. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
    FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M.
    Lancet Respir Med; 2018 Jan 29; 6(1):51-64. PubMed ID: 28919200
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L, Newbold P, Wu Y, Trudo F.
    Allergy Asthma Proc; 2018 Sep 04; 39(5):345-349. PubMed ID: 30077185
    [Abstract] [Full Text] [Related]

  • 10. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
    Chipps BE, Hirsch I, Trudo F, Alacqua M, Zangrilli JG.
    Ann Allergy Asthma Immunol; 2020 Jan 04; 124(1):79-86. PubMed ID: 31626906
    [Abstract] [Full Text] [Related]

  • 11. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M, BISE Study Investigators.
    Lancet Respir Med; 2017 Jul 04; 5(7):568-576. PubMed ID: 28545978
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma.
    Ohta K, Adachi M, Tohda Y, Kamei T, Kato M, Mark Fitzgerald J, Takanuma M, Kakuno T, Imai N, Wu Y, Aurivillius M, Goldman M.
    Allergol Int; 2018 Apr 04; 67(2):266-272. PubMed ID: 29128192
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment.
    Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Brooks L, Olsson RF, Martin UJ, Goldman M, BORA study investigators.
    J Allergy Clin Immunol; 2021 Jul 04; 148(1):266-271.e2. PubMed ID: 33609624
    [Abstract] [Full Text] [Related]

  • 15. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.
    Bourdin A, Shaw D, Menzies-Gow A, FitzGerald JM, Bleecker ER, Busse WW, Ferguson GT, Brooks L, Barker P, Gil EG, Martin UJ.
    J Asthma; 2021 Apr 04; 58(4):514-522. PubMed ID: 31859541
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.
    Criner GJ, Celli BR, Singh D, Agusti A, Papi A, Jison M, Makulova N, Shih VH, Brooks L, Barker P, Martin UJ, Newbold P.
    Lancet Respir Med; 2020 Feb 04; 8(2):158-170. PubMed ID: 31575508
    [Abstract] [Full Text] [Related]

  • 18. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG.
    Lancet Respir Med; 2014 Nov 04; 2(11):879-890. PubMed ID: 25306557
    [Abstract] [Full Text] [Related]

  • 19. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, Humbert M, Castro M, Marsteller DA, McElhattan J, Hickey L, Garin M, Vanlandingham R, Brusselle G.
    Lancet Respir Med; 2020 May 04; 8(5):461-474. PubMed ID: 32066536
    [Abstract] [Full Text] [Related]

  • 20. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A.
    Lancet; 2016 Jul 02; 388(10039):31-44. PubMed ID: 27130691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.